Suppr超能文献

[一例因对狂犬病疫苗成分过敏,通过皮内注射狂犬病疫苗进行暴露前免疫的病例]

[A case received pre-exposure immunization against rabies by intradermal injection of rabies vaccine because of allergic reaction to the component of the vaccine].

作者信息

Takayama N, Okuma K, Sakuma H

机构信息

Department of Pediatrics, Tokyo Metropolitan Komagome Hospital.

出版信息

Kansenshogaku Zasshi. 1999 Jun;73(6):600-1. doi: 10.11150/kansenshogakuzasshi1970.73.600.

Abstract

A female, 25 years of age, came to our clinic to receive pre-exposure immunization against rabies. In another hospital she was tested to find out whether she was allergic to the components of rabies vaccine (PCEC) manufactured by the Chemo-Sero-Theraptic Research Institute (Kaketsuken) by cutaneous reaction using a 2,000-fold diluted PCEC. She showed a positive reaction. In our clinic she was again examined by skin test using 0.1 ml of 10-fold diluted PCEC. She showed wheal and flare reaction. Further we tested using 0.05 ml and 0.1 ml of non-diluted PCEC. Her skin reaction did not increase by several mm in diameter. So we decided to immunized her against rabies with intradermal injections of PCEC instead of subcutaneous injections that is indicated by the manufacturer. The second intradermal injections were done to right and left forearms a week later. Then the third shot was given 4 weeks after the second. At 2 weeks after the third injection her blood sample was taken to measure anti-rabies antibody titer by ELISA method with Platelia rabies kit (Diagnostic Pasteur, France). She had 6.7 U/ml of anti-rabies ELISA antibody that was much higher than the protective level (0.5 IU/ml) officially recognized by WHO. Therefore, it is concluded that she had produced sufficiently high level of anti-rabies antibody with intradermal injection of PCEC. It is reasonably recommended to investigate further if the intradermal injection of PCEC will be an effective method as a pre-exposure immunization against rabies.

摘要

一名25岁女性前来我们诊所接受狂犬病暴露前免疫。在另一家医院,她通过使用2000倍稀释的日本化学及血清疗法研究所(Kaketsuken)生产的狂犬病疫苗(PCEC)进行皮肤反应测试,以确定她是否对该疫苗成分过敏。她呈阳性反应。在我们诊所,我们再次用0.1毫升10倍稀释的PCEC对她进行皮肤试验。她出现了风团和红晕反应。此外,我们还用0.05毫升和0.1毫升未稀释的PCEC进行了测试。她的皮肤反应直径并未增加几毫米。因此,我们决定用PCEC皮内注射而非制造商建议的皮下注射为她进行狂犬病免疫。一周后在左右前臂进行了第二次皮内注射。然后在第二次注射4周后进行了第三次注射。在第三次注射后2周,采集她的血样,使用法国巴斯德诊断公司的Platelia狂犬病试剂盒通过ELISA方法检测抗狂犬病抗体滴度。她的抗狂犬病ELISA抗体为6.7 U/ml,远高于世界卫生组织官方认可的保护水平(0.5 IU/ml)。因此,可以得出结论,她通过PCEC皮内注射产生了足够高水平的抗狂犬病抗体。合理建议进一步研究PCEC皮内注射作为狂犬病暴露前免疫的有效方法。

相似文献

9
Intradermal pre-exposure rabies immunisation in New Zealand.新西兰的皮内暴露前狂犬病免疫
Travel Med Infect Dis. 2006 Jan;4(1):29-33. doi: 10.1016/j.tmaid.2004.11.005. Epub 2005 Jan 7.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验